← Back to Clinical Trials
Recruiting NCT04443530

NCT04443530 Evaluation of Effectiveness and Safety of Ultimaster™ Tansei™ Stent and/or Ultimaster Nagomi™ Stent in Routine Clinical Practice

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04443530
Status Recruiting
Phase
Sponsor Duk-Woo Park, MD
Condition Coronary Artery Disease
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2020-09-17
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 19 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Ultimaster™ Tansei™ stent and/or Ultimaster Nagomi™ stent

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2020-09-17 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is to evaluate the effectiveness and safety of Ultimaster Tansei stent and/or Ultimaster Nagomi stent in the "real-world" daily practice.

Eligibility Criteria

Inclusion Criteria: 1. Patients ≥ 19 years old 2. Patients receiving Ultimaster™ Tansei™ stent and/or Ultimaster Nagomi™ stents. 3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site. Exclusion Criteria: 1. Patients with a mixture of other drug-eluting stents (DESs) 2. Terminal illness with life-expectancy ≤1 year. 3. Patients with cardiogenic shock

Contact & Investigator

Central Contact

Jung-hee Ham, RN

✉ cvcrc5@amc.seoul.kr

📞 82230104728

Frequently Asked Questions

Who can join the NCT04443530 clinical trial?

This trial is open to participants of all sexes, aged 19 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04443530 currently recruiting?

Yes, NCT04443530 is actively recruiting participants. Contact the research team at cvcrc5@amc.seoul.kr for enrollment information.

Where is the NCT04443530 trial being conducted?

This trial is being conducted at Chuncheon, South Korea, Daegu, South Korea, Daegu, South Korea, Daejeon, South Korea and 7 additional locations.

Who is sponsoring the NCT04443530 clinical trial?

NCT04443530 is sponsored by Duk-Woo Park, MD. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology